서울대학교 생물정보학 협동과정 주최로 세미나를 아래와 같이 열고자 하오니 많은 참여 바랍니다.

세미나는 Zoom을 통한 온라인 강의로 예정되어 있으며 강의에 참여하고자 하시는 분께서는 아래의 링크로 참여 부탁드리겠습니다.

*줌으로 참석하기 위해서는 "참석자로 회의 참가" --> 이름, 성, 이메일 주소, 이메일 주소 확인을 입력하시고 등록하시면 회의 참석이 가능합니다.

일시: 2024년 4월 30일 화요일 오전 11시

연사: 김락균 교수님 (연세대학교)

Zoom link: https://snu-ac-kr.zoom.us/j/84584436199?pwd=PArzymsIeWaJCaKq81hpEmqcv9vJTZ.1

Title: Epigenomic Profiling of Papillary Thyroid Carcinoma Reveals Distinct Subtypes with Clinical Implications

Abstract:

Purpose

In pursuit of a minimally invasive method for predicting the aggressiveness of papillary thyroid cancer (PTC), we aimed to develop a prediction system utilizing epigenetic biomarkers that would remain effective even when using fine-needle aspiration biopsy (FNAB) samples.

Experimental Design

After a thorough analysis of publicly available methylome data, we identified approximately 7,200 CpG island regions with altered methylation levels in the tissues of patients with thyroid cancer. These regions were comprehensively analyzed at the single-CpG site level using samples from a cohort of 55 patients with PTC. Subsequently, methyl-specific primers were designed and validated for the selected regions that showed the most significant changes, enabling detection through real-time PCR.

Results

Based on the methylation patterns observed within our region of interest, our cohort was divided into two groups. Patients from publicly available data were stratified into two groups that exhibited patterns similar to those observed in our cohort, with one group showing a poorer survival rate. Our methyl-specific primers successfully distinguished the FNAB samples obtained from patients with PTC into two distinct types.

Conclusions

Utilizing epigenetic biomarkers, we developed a system to predict PTC aggressiveness and demonstrated its effectiveness in FNAB samples. By analyzing methylome data and validating our findings in a cohort of patients with PTC, we identified distinct methylation patterns that allowed the stratification of patients into two groups, with implications for survival prognosis. Additionally, our methyl-specific primers show promise for accurately categorizing FNAB samples, providing a potential tool for clinical assessment and personalized treatment strategies.